This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Les Laboratoires Servier, Allogene Therapeutics, Inc.. Active years: 2025-2026.
Company Filing History:
2 out of 296 
1 out of 20 Years Active: 2025-2026
Title: Amina Zinai: Innovator in Chimeric Antigen Receptor T Cell Therapy
Introduction
Amina Zinai is a prominent inventor based in Paris, France. She has made significant contributions to the field of immunotherapy, particularly in the development of methods for administering chimeric antigen receptor (CAR) T cells. Her work is crucial for advancing treatments for diseases such as cancer.
Latest Patents
Amina Zinai holds 1 patent titled "Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells." This patent focuses on dosages for the treatment of human patients who are susceptible to or diagnosed with diseases like cancer. The disclosure includes methods for administering CAR-T cells, as well as compositions and articles of manufacture for use in these methods.
Career Highlights
Throughout her career, Amina has worked with notable companies in the biotechnology sector. She has been associated with Allogene Therapeutics, Inc. and Les Laboratoires Servier, where she has contributed her expertise in the development of innovative therapies.
Collaborations
Amina Zinai has collaborated with Cyril Alkis Konto, enhancing her research and development efforts in the field of CAR-T cell therapy.
Conclusion
Amina Zinai's work in the field of immunotherapy exemplifies her dedication to advancing medical treatments for cancer patients. Her innovative approaches and collaborations continue to pave the way for future breakthroughs in this critical area of healthcare.